CAS: 495399-09-2; (S)-2-Ethoxy-3-(4-(2-(2-Methyl-5-(4-(Methylthio)Phenyl)-1H-Pyrrol-1-yl)Ethoxy)Phenyl)Propanoic Acid

上下游产品

Methanesulfonic Acid 2-[2-Methyl-5-(4-Methylsulfanylphenyl)Pyrrol-1-Yl]Ethyl Ester 494850-87-2

📜(S)-(-)α-1-Phenylethylamine Salt Of (S)-α-Ethoxy-4-[2-[-Methyl-5-[4-(Methylthio) Phenyl]-1H-Pyrrol-1-Yl]Ethoxy]Benzene-Propanoic Acid置于盐酸,水体系中,用 乙酸乙酯 作为反应溶剂,化学反应 0.17H,反应生成 萨格列扎
参考文献: Novel Salts,Crystalline Forms And Premix Of Hypolipidemic Agent[fr] Nouveaux Sels,Formes Cristallines Et Prémélange D'Agent Hypolipidémique
标题: Novel Salts,Crystalline Forms And Premix Of Hypolipidemic Agent[fr] Nouveaux Sels,Formes Cristallines Et Prémélange D'Agent Hypolipidémique
摘要:本发明涉及萨罗格利他新型盐和某些萨罗格利他盐的多晶形式.本发明提供了制备新型盐和多晶形式的方法.本发明还提供了萨罗格利他与药学上可接受的辅料/次级治疗剂的新型共沉淀剂或预混合物,以及其制备方法.

专利信息

专利号:US-9550719-B2
优先权日:2013-05-09
标题 :Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds
发明人：MURUGAN MUTHUKRISHNAN; MOHAMMAD MUJAHID
权利人:COUNCIL SCIENT IND RES
摘要:The present disclosure provides a process for synthesis of 3-aryl-2-hydroxy propanoic acid derivatives of formula (S)-1. wherein R 1 represents H or (C 1 -C 5 ) alkyl groups and R 2 represents (C 1 -C 5 ) alkyl groups.

专利号:US-12358903-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-11739065-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.